China Shanghai International Pharmaceutical Raw Materials Exhibition Tickets

This article provides an overview of API China, the China International Pharmaceutical Active Ingredients Exhibition. As one of the longest-running trade shows in China’s pharmaceutical sector, API China showcases a comprehensive range of products, including active pharmaceutical ingredients, excipients, functional additives, primary and secondary packaging materials, as well as manufacturing and analytical equipment. With the ongoing implementation of generic drug bioequivalence assessments and

The Exhibition Value of API China

• API China is the longest-running and largest specialized trade show in China’s pharmaceutical industry. Since its inception in 1968, it has been successfully held for more than ninety editions and is widely recognized by the industry as a leading indicator of trends in China’s pharmaceutical sector and a central hub of the global pharmaceutical raw-materials supply chain. Co-organized by the China Chamber of Commerce for Import & Export of Medicines & Health Products and Reed Sinopharm, the event has cultivated deep roots in the industry for nearly six decades. It stands as an indispensable annual gathering for the entire pharmaceutical R&D and manufacturing value chain, often hailed as the “barometer” of China’s pharmaceutical industry.
• The core value of participating lies in its unparalleled ability to cover the entire industry chain and its unique platform that precisely connects with key buyers in China’s pharmaceutical sector. The exhibition showcases dozens of major product categories—ranging from pharmaceutical APIs and excipients to pharmaceutical packaging, manufacturing equipment, natural products, and biopharmaceutical supply-chain solutions—encompassing tens of thousands of items. From R&D through production, packaging, and distribution, it forms a complete industrial ecosystem. Each edition attracts nearly 5,000 pharmaceutical companies from across the country, with 97% of China’s top 100 pharmaceutical enterprises sending delegation-level participation. For API and excipient manufacturers, it is the preferred platform for entering China’s pharmaceutical supply chain and expanding into the domestic market.
• The exhibition aligns closely with three major industry trends—integrated API–formulation development, green manufacturing, and internationalization—thereby establishing a cutting-edge technological hub characterized by deep integration among industry, academia, research, and application. Driven by policies promoting centralized volume-based procurement, integrated API–formulation development has become the mainstream trend. Through the release of authoritative industry reports and policy‑interpretation forums, the exhibition provides robust support to help companies define their strategic direction. Concurrently, more than fifty high‑profile industry forums are held, addressing hot topics such as innovative drug R&D, technological upgrades, policy analysis, and overseas market expansion, with nearly one hundred renowned industry experts sharing their insights.
• For Chinese enterprises, this exhibition serves as a strategic gateway for tapping the domestic market, connecting with global resources, and showcasing their innovative capabilities. As a vital platform for international brands seeking to enter the Chinese market, globally recognized companies such as Rousselot, Capsugel, Sanofi, Merck, and Evonik have leveraged API China to establish relationships with Chinese customers and rapidly expand their operations in China. At the same time, the exhibition seamlessly integrates online and offline services, offering year-round, precision‑matched business‑opportunity matchmaking to help companies transcend geographical and temporal constraints and reach global audiences. Participating enterprises can use this platform to connect with China’s core procurement networks, seizing early opportunities in the high‑quality development of the pharmaceutical industry.